---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-338000"
form_type: "8-K"
ticker: "TECX"
cik: "0001681087"
company_name: "Tectonic Therapeutic, Inc."
filed_at: "2026-08-06T20:10:06+00:00"
generated_at: "2026-08-06T20:13:41.858539+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Tectonic Q2 net loss $22.3M; cash $227M; TX45 Phase 2 enrollment complete, IDMC recommends continuation

## Summary
- Net loss of $22.3M for Q2 2026 vs $20.0M in Q2 2025; R&D expenses $18.0M, G&A $6.2M.
- Cash and cash equivalents $227.1M as of June 30, 2026; cash runway into Q1 2029.
- TX45 APEX Phase 2 trial in PH-HFpEF completed enrollment (191 patients, 137 with CpcPH); IDMC recommended continuation; topline results expected early Q1 2027.
- TX2100 Phase 1a single dose cohorts completed; topline results expected by end of Q3 2026; Phase 2 planned early 2027.

## SEC filing metadata
- accession: 0001193125-26-338000
- form_type: 8-K
- ticker: TECX
- cik: 0001681087
- company_name: Tectonic Therapeutic, Inc.
- filed_at: 2026-08-06T20:10:06+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681087/000119312526338000/0001193125-26-338000-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681087/000119312526338000/d114671d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-338000
- JSON: https://secwatch.observer/filing/0001193125-26-338000.json
- Plain text: https://secwatch.observer/filing/0001193125-26-338000.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.